Pseudomyxoma peritonei syndrome of appendiceal origin: an overview.
Pseudomyxoma peritonei (PMP) syndrome is an uncommon, slowly progressive condition that usually arises from perforation of an adenoma in the appendix. PMP syndrome is characterized by mucin accumulation in the peritoneal cavity. Mucinous implants are found on all peritoneal surfaces and the omentum. PMP syndrome rarely metastasizes outside the abdominal cavity but remains a fatal illness as the space in the abdomen and pelvis required for normal function of the gastrointestinal tract becomes filled with copious amounts of the mucinous tumor. Treatment options include observation, aggressive debulking surgery, intraperitoneal chemotherapy, radiotherapy, and mucolytic agents.
Brueggen
Carol
C
College of Medicine, Mayo Clinic, Rochester, MN, USA. brueggen.carol@mayo.edu
Baird
Gayle
G
Meisheid
Allison
A
D000359:Aftercare; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001063:Appendiceal Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006801:Humans; D015994:Incidence; D007263:Infusions, Parenteral; D009859:Oncology Nursing / Q000458:organization & administration; D010166:Palliative Care; D010347:Patient Care Planning; D010533:Peritoneal Lavage; D010534:Peritoneal Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D011187:Posture; D011553:Pseudomyxoma Peritonei / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D035583:Rare Diseases; D013577:Syndrome; D014057:Tomography, X-Ray Computed; D014481:United States / Q000453:epidemiology
D000970:Antineoplastic Agents